- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06716242
Validace testu MaiRa preeklampsie pro screening časné/pozdní preeklampsie v prvním a druhém trimestru (iPregnostic)
Prospektivní, observační, multicentrická studie k potvrzení účinnosti molekulárního screeningu pro časnou detekci preeklampsie
Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions.
Current screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that incorporate maternal factors and Doppler metrics remain constrained by low sensitivity (<41%) in compliance with NICE and ACOG guidelines.
Recent advancements in cell free RNA (cf-RNA) analysis have revealed potential in first-trimester PE prediction. Findings from the PREMOM study (NCT04990141) established a molecular profile for early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) through cfRNA analysis, culminating in the development of the MaiRa Preeclampsia Test (Maternal Advanced and Innovative Preeclampsia Risk Assessment), which demonstrated high predictive performance for first- and second-trimester screening.
The current study hypothesizes that the MaiRa Preeclampsia Test is generalizable, maintaining its predictive accuracy in an independent cohort.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This multicentre, prospective observational study aims to validate the MaiRa Preeclampsia Test, a molecular screening tool for predicting early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) in the first and second trimesters of pregnancy. The study will evaluate its diagnostic accuracy, including sensitivity, specificity, predictive values, and area under the curve (AUC).
Study Design:
Duration: 40 months
- Recruitment and Sample Collection: 28 months
- Sample Analysis: 32 months
- Follow-Up: 8 months
- Statistical Analysis and Publication: 6 months Participants: 7,473 pregnant women from 12 tertiary hospitals in Spain.
Visits:
- Visit 1 (T1): 9-14 weeks' gestation (first blood sample)
- Visit 2 (T2): 15-26 weeks' gestation (second blood sample)
- Visit 3 (T3): ≥27 weeks' gestation (third blood sample)
Blood samples will be analyzed using the MaiRa Preeclampsia Test, with results correlated against obstetric outcomes as the gold standard. Data will be documented in an electronic Case Report Form (eCRF). Quality assurance will be maintained via continuous data monitoring and verification.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní místa
-
-
Alicante
-
Alicante, Alicante, Španělsko, 03010
- Hospital General Universitario Dr. Balmis
-
-
Barcelona
-
Barcelona, Barcelona, Španělsko, 08025
- Hospital de la Santa Creu i Sant Pau
-
-
Castellón
-
Vinaròs, Castellón, Španělsko, 12500
- Hospital Comarcal de Vinaròs
-
-
Cádiz
-
Cadiz, Cádiz, Španělsko, 11009
- Hospital Universitario Puerta del Mar
-
-
La Coruña
-
A Coruña, La Coruña, Španělsko, 15006
- Hospital Universitario A Coruña
-
-
Madrid
-
Torrejón de Ardoz, Madrid, Španělsko, 28850
- Hospital Universitario de Torrejón
-
-
Murcia
-
El Palmar, Murcia, Španělsko, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Santa Cruz de Tenerife
-
San Cristóbal de La Laguna, Santa Cruz de Tenerife, Španělsko, 38320
- Hospital Universitario de Canarias
-
-
Valencia
-
Manises, Valencia, Španělsko, 46940
- Hospital de Manises
-
Valencia, Valencia, Španělsko, 46017
- Hospital Universitario Doctor Peset
-
Valencia, Valencia, Španělsko, 46026
- Hospital Universitario y Politécnico La Fe
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Pregnant patients aged 18 years or older, recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals.
Popis
Inclusion Criteria:
- Signed informed consent approved by the Ethics Committee.
- Women ≥18 years of age at consent.
- Single gestation pregnancies with first sample collection (T1) possible between 9 and 14 weeks' gestation.
Exclusion Criteria:
- Active neoplasm.
- History of organ or bone marrow transplantation.
- Maternal transfusion within 8 weeks before sample collection.
- Evidence of early pregnancy loss at consent.
- Severe, uncontrolled infections.
- Other investigator-assessed risks that could compromise participation or data quality.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Pregnant patients aged 18 years or older
Pregnant patients aged 18 years or older recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals. |
Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Validation of the MaiRa Preeclampsia Test for first-trimester screening (9-14 weeks) of EOPE
Časové okno: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Validation of second-trimester screening (15-26 weeks) for EOPE
Časové okno: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Validation of second-trimester screening (15-26 weeks) for LOPE
Časové okno: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Exploratory outcome: Validation of first-trimester screening (9-14 weeks) for LOPE
Časové okno: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Validation of first and second trimester screening for other pregnancy complications
Časové okno: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Other pregnancy complications such as preterm labour, intrauterine growth restriction, gestational diabetes and placenta previa among others. Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Molecular characterization of cfRNA and other biomarkers across gestation
Časové okno: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
DNA/RNA/proteins/metabolites associated with gestational age and clinical outcomes. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Identification of candidate biomarkers in maternal blood for therapeutic interventions
Časové okno: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Molecular characterization (DNA/RNA/proteins/metabolites). |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Carlos Simón, MD, PhD, Carlos Simon Foundation
- Vrchní vyšetřovatel: Tamara Garrido, PhD, iPremom
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- IPR-IPR-TG-24-01
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .